Last Friday Genocea (NASDAQ: GNCA) faced a big 69.23% loss that was caused by early data from Gen-011 in pretreated patients with solid tumors. Those who feared that the potential candidate isn’t reliable for the current trials sold millions of shares. The majority of traded 11.2 million shares on Friday were sold.
GNCA stock soars in premarket
After investors realize that Gen-011 isn’t showing only bad results and the upcoming trials may bring good data in treating the solid tumor, most of the thorough researching buyers have just jumped onto the GNCA bandwagon by hoping that the candidate won’t fail them. Right now the stock is rocketing 50% on seven million shares. GNCA may keep rising higher after the market opens.